Home>>Signaling Pathways>> Neuroscience>> COX>>Tenoxicam

Tenoxicam (Synonyms: Ro 12-0068)

Catalog No.GC10006

antiinflammatory agent

Products are for research use only. Not for human use. We do not sell to patients.

Tenoxicam Chemical Structure

Cas No.: 59804-37-4

Size Price Stock Qty
10mM (in 1mL DMSO)
$39.00
In stock
500mg
$35.00
In stock
1g
$56.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Tenoxicam (Ro-12-0068), an antiinflammatory agent with analgesic and antipyretic properties.

Tenoxicam (Ro-12-0068) is a non-steroidal anti-inflammatory drug (NSAID)[1].

Tenoxicam (Ro-12-0068) was administered intraperitoneally immediately after BCAO. Histological analyses show that ischemia produced significant striatal as well as hippocampal lesions which were reversed by the Tenoxicam (Ro-12-0068) treatment. Tenoxicam (Ro-12-0068) also significantly reduced, to control levels, the increased myeloperoxidase activity in hippocampus homogenates observed after ischemia[2].

References:
[1]. Ozgocmen, S., et al., In vivo effect of celecoxib and tenoxicam on oxidant/ anti-oxidant status of patients with knee osteoarthritis. Ann Clin Lab Sci, 2005. 35(2): p. 137-43.
[2]. Galvao, R.I., et al., Tenoxicam exerts a neuroprotective action after cerebral ischemia in rats. Neurochem Res, 2005. 30(1): p. 39-46.

Reviews

Review for Tenoxicam

Average Rating: 5 ★★★★★ (Based on Reviews and 40 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tenoxicam

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.